opentrade on 
↗
↗event5 outcomes
Will the FDA approve camizestrant for advanced breast cancer?
·Science and Technology·ends Jan 8, 2028vol cum
$8.1k
vol 24h
$33
outcomes
5
ends
Jan 8, 2028
outcomesclick to inspect →
marketselected outcome
Before Jan 1, 2028
rank #1
United States
70¢
· 0.0pp
24h change
vol cum
$91
vol 24h
$0
spread
0.06
ends
Jan 8, 2028
If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jan 1, 2028, then the market resolves to Yes.
timeline
opened · May 14, 2026opencloses · Jan 8, 2028
Before Jan 1, 2028 · prices over time
−24h
now
volume · by outcomehover a column to inspect
no volume history
similar markets
suggested by pdatakalshiWill the FDA approve retatrutide?
Before Jul 1, 202747¢· 0.0ppBefore Jan 1, 202999¢· 0.0ppBefore Jul 1, 202887¢· 0.0pp
+2 others
$12 24h · 5 markets
polymarketFDA approves Retatrutide this year?
yes3¢▼ 0.1pp
$0 24h · 1 market
The FDA will approve an AI developed cure before the end of the decade (<2030) for a previously incurable major illness.
yes26¢· 0.0pp
M0 24h · 1 market
kalshiWill the FDA approve CagriSema?
Before Jul 1, 202784¢· 0.0ppBefore Jan 1, 202776¢· 0.0ppBefore Jan 1, 202876¢· 0.0pp
+2 others
$0 24h · 5 markets
polymarketFDA approves Daraxonrasib this year?
yes89¢· 0.0pp
$0 24h · 1 market
Will AOH1996 be FDA approved before 2040?
yes40¢· 0.0pp
M0 24h · 1 market